Praxis Precision's New Drug Application for Relutrigine Accepted for Priority Review by FDA
Praxis Precision announced that the FDA has accepted for priority review its new drug application for relutrigine, for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies. The FDA has set a target action date under the Prescription Drug User Fee Act of September 27.
